The in vivo quantification of the receptor site concentration using ligand-receptor interaction modeling

Drug Information Journal

Volumn 31, Issue 3, 1997, Pages 1019-1027

  Delforge, Jacques ^a  

^a SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

Author keywords

Affinity; Ligand; Lipophilicity; Modeling; Positron emission tomography; Receptor

Indexed keywords

LIGAND; RECEPTOR;

ARTICLE; BINDING SITE; LIPOPHILICITY; MATHEMATICAL MODEL; MODEL; POSITRON; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0030751797     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159703100346     Document Type: Article

References (27)

1. Syrota A, Paillotin G, Davy JM, Aumont MC. Kinetics of in vivo binding of antagonist to muscarinic cholinergic receptor in the human heart studied by positron emission tomography. Life Sci. 1984;35: 937-945.
2. Perlmutter JS, Larson KB, Raichle ME, Markham J, Mintun MA, Kilbourn MR, Welch MJ. Strategies for in vivo measurement of receptor binding using positron emission tomography. J Cereb Blood Flow Metab. 1986;6:154-169.
3. Wong DK, Gjedde A, Wagner HN. Quantification of neuroreceptors in the living human brain, I, Irreversible binding of ligands. J Cereb Blood Flow Metab. 1986;6:137-146.
4. Delforge J, Janier M, Syrota A, Crouzel C, Vallois JM, Cayla J, Lancon JP, Mazoyer BM. Noninvasive quantification of muscarinic receptors in vivo with positron emission tomography in the dog heart. Circulation. 1990;82:1494-1504.
5. Delforge J, Syrota A, Mazoyer B. Experimental design optimization: theory and application to estimation of receptor model parameters using dynamic positron emission tomography. Phys Med Biol. 1989; 34:419-435.
6. Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living brain by PET. Science. 1986;231:258-261.
7. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol. 1984;15:217-227.
8. Delforge J, Bendriem B, Syrota A. The concept of reaction volume in the in vivo ligand-receptor model. J Nucl Med. 1996;37:118-125.
9. 11C]flumazenil kinetics studied by PET: application to a critical study of the equilibrium approaches. J Cereb Blood Flow Metab. 1993;13:454-468.
10. 76Br-Bromolisuride binding to dopamine D2 receptors studied by PET. J Cereb Blood Flow Metab. 1991;11:914-925.
11. Huang SH, Barrio JB, Phelps ME. Neuroreceptor assay with positron emission tomography: equilibrium versus dynamic approaches. J Cereb Blood Flow Metab. 1986;6:515-521.
12. Kessler RM, Ansari MS, De Paulis T, Schmidt DE, Clanton JA, Smith HE, Manning RG, Gillespie D, Ebert MH. High affinity dopamine D2 receptor radioligands. Regional rat brain distribution of Iodinated benzamides. J Nucl Med. 1991;32:1593-1600.
13. Frost JJ, Wagner HN. Kinetics of binding to opiate receptors in vivo predicted from the in vitro parameters. Brain Research. 1984;305:1-11.
14. 11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab. 1991; 11:735-744.
15. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constant from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1-7.
16. Delforge J, Le Guludec D, Syrota A, Bendriem B, Crouzel C, Slama M, Merlet M. Quantification of myocardial muscarinic receptors with PET in humans. J Nucl Med. 1993;34:981-991.
17. 11C]flumazenil kinetics studied by PET: application to a critical study of the equilibrium approaches. J Cereb Blood Flow Metab. 1995;13:454-468.
18. Delforge J, Syrota A, Lancon JP, Nakajima K, Loc'h C, Janier M, Vallois JM, Cayla J, Crouzel C. Cardiac beta-adrenergic receptor density measured in vivo using PET, CGP 12177 and a new graphical method. J Nucl Med. 1991;32:739-748.
19. Le Guludec D, Delforge J, Syrota A, Desruennes M, Valette H, Gandjbakhch I, Merlet P. In vivo quantification of myocardial muscarinic receptors in heart transplant patients. Circulation. 1994;99:172-178.
20. Merlet P, Delforge J, Syrota A, Angevin E, Mazière B, Crouzel C, Valette H, Loisance D, Castaigne E, Dubois-Rande JL. Positron emission tomography with C11-CGP 12177 to assess beta-adrenergic receptor concentration in idiopathic dilated cardiomyopathy. Circulation. 1993;87:1169-1178.
21. 11C]RO 15 1788 to central type benzodiazepine receptors in human brain: quantitative evaluation by PET. J Cereb Blood Flow Metab. 1988;8:304-313.
22. Savic I, Persson A, Roland P, Pauli S, Sedvall G, Widen L. In vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci. Lancet. 1988;2:863-866.
23. d values with positron emission tomography. Eur J Pharmacol. 1992;213:107-115.
24. Blomqvist G, Pauli S, Farde L, Eriksson L, Persson A, Halldin C. Maps of receptor binding parameters in the human brain - A kinetic analysis of PET measurements. Eur J Nucl Med. 1990;16:257-265.
25. Delforge J, Spelle L, Bendriem B, Samson Y, Bottlaender M, Papageorgiou S, Syrota A. Quantitation of the benzodiazepine receptor in human brain using a partial-saturation method. Nucl Med. 1996b;37: 5-11.
26. 11C]flumazenil and PET: application of the steady-state principle. J Cereb Blood Flow Metab. 1995;15:152-165.
27. Millet P, Delforge J, Mauguière F, Pappata S, Cinotti L, Frouin V, Samson Y, Bendriem B, Syrota A. Parametric images of benzodiazepine receptor concentration in human brain: comparison with the distribution volume approach. J Nucl Med. 1995;36: 1462-1471.